Previous 10 | Next 10 |
New drug application (NDA) seeks U.S. Food and Drug Administration (FDA) approval for VOQUEZNA® as a daily treatment for heartburn associated with Non-Erosive GERD, the largest subcategory of GERD July 19, 2024 PDUFA target action date assigned by the FDA FLORHAM PARK, ...
VOQUEZNA, the first and only FDA-approved potassium-competitive acid blocker (PCAB), is now available through major retail pharmacies and BlinkRx, an end-to-end digital fulfillment channel VOQUEZNA tablets in 30-count bottles are now commercially available for the healing and ...
Phathom Pharmaceuticals Inc. (PHAT) is expected to report $-0.95 for Q3 2023
2023-11-09 17:15:33 ET More on Phathom Pharmaceuticals Following Up On Phathom Pharmaceuticals Phathom Pharmaceuticals gets FDA approval for Erosive GERD drug Phathom wins FDA nod for reformulated antibiotic For further details see: Phantom Pharmaceutical...
2023-11-09 09:07:48 ET More on Phathom Pharmaceuticals Following Up On Phathom Pharmaceuticals Phathom Pharmaceuticals gets FDA approval for Erosive GERD drug Phathom wins FDA nod for reformulated antibiotic Seeking Alpha’s Quant Rating on Phathom Phar...
VOQUEZNA® (vonoprazan) tablets approved by the U.S. Food and Drug Administration (FDA) for the treatment of Erosive GERD and relief of associated heartburn in adults, marking the first major innovation in the U.S. Erosive GERD market in over 30 years Commercial availability of VOQUEZNA f...
2023-11-01 17:45:03 ET More on Phathom Pharmaceuticals Following Up On Phathom Pharmaceuticals Phathom wins FDA nod for reformulated antibiotic Phathom files for FDA approval of vonoprazan for Non-Erosive GERD Seeking Alpha’s Quant Rating on Phathom Ph...
FDA approval marks the first major innovation to the U.S. Erosive GERD market in over 30 years VOQUEZNA ® met the primary endpoints and key secondary superiority endpoints in the pivotal Phase 3 PHALCON-EE trial evaluating VOQUEZNA in comparison to a standard-of-care proton pump in...
2023-10-30 12:32:31 ET More on Phathom Pharma Following Up On Phathom Pharmaceuticals Phathom files for FDA approval of vonoprazan for Non-Erosive GERD Phathom submits additional data to FDA for esophagitis candidate Seeking Alpha’s Quant Rating on Pha...
Planning for a December 2023 U.S. launch for H. pylori , together with the U.S. launch of vonoprazan for Erosive GERD, if approved FLORHAM PARK, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on develop...
News, Short Squeeze, Breakout and More Instantly...
Phathom Pharmaceuticals Inc. Company Name:
PHAT Stock Symbol:
NYSE Market:
First oral presentation of Phase 3 data evaluating the investigational use of VOQUEZNA® in Non-Erosive Reflux Disease (NERD) 1 New research on Erosive gastroesophageal reflux disease (GERD) demonstrating high health care resource utilization, real ...